StreetInsider.com News Articles

Form SCHEDULE 13D Vivos Therapeutics, Inc. Filed by: V-Co Investors 4 LLC

Wed, 15 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26774909.html

Form SCHEDULE 13D Vivos Therapeutics, Inc. Filed by: V-Co Investors 4 LLC

Wed, 15 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26774909.html

Form 4 Vivos Therapeutics, Inc. For: Jun 30 Filed by: Skaff Michael C

Wed, 15 Jul 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260715/26774429.html

Form 4 Vivos Therapeutics, Inc. For: Jun 30 Filed by: Skaff Michael C

Wed, 15 Jul 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260715/26774429.html

Form 3 Vivos Therapeutics, Inc. For: Jun 30 Filed by: V-Co Investors 4 LLC

Wed, 15 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260715/26774409.html

Form 3 Vivos Therapeutics, Inc. For: Jun 30 Filed by: V-Co Investors 4 LLC

Wed, 15 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260715/26774409.html

Form 8-K Vivos Therapeutics, Inc. For: Jul 07

Tue, 07 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260707/26742814.html

Form 8-K Vivos Therapeutics, Inc. For: Jul 07

Tue, 07 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260707/26742814.html

Vivos reports insomnia improvement in small Vida appliance study

Tue, 30 Jun 2026 08:46:57 -0400

Vivos Therapeutics, Inc. (NASDAQ: VVOS) released clinical data from a single-site study showing its Vida® oral appliance produced statistically significant reductions in insomnia severity among all 37 participants, according to a company press release.

The study, conducted between 2022 and 2025, enrolled adults aged 28 to 77 with moderate to severe insomnia as measured by the Insomnia Severity Index (ISI). Participants wore the appliance nightly for an average of 3.7 months. The company reported an average ISI score reduction of approximately 65%, with every participant improving by at least one ISI classification level. The study reported a p-value of approximately 0.0000001.

The

Vivos reports insomnia improvement in small Vida appliance study

Tue, 30 Jun 2026 08:46:57 -0400

The

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Tue, 30 Jun 2026 08:45:00 -0400

LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compelling clinical data showing that treatment with its FDA‑cleared Vida^® oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants, underscoring what the Company believes could be a major new commercial opportunity in the large and underserved global insomnia market.

Newly Released Vida^® Data Supports Potential

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Tue, 30 Jun 2026 08:45:00 -0400

LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compelling clinical data showing that treatment with its FDA‑cleared Vida^® oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants, underscoring what the Company believes could be a major new commercial opportunity in the large and underserved global insomnia market.

Newly Released Vida^® Data Supports Potential

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Tue, 30 Jun 2026 08:45:00 -0400

LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compelling clinical data showing that treatment with its FDA‑cleared Vida^® oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants, underscoring what the Company believes could be a major new commercial opportunity in the large and underserved global insomnia market.

Newly Released Vida^® Data Supports Potential

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Tue, 30 Jun 2026 08:45:00 -0400

LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compelling clinical data showing that treatment with its FDA‑cleared Vida^® oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants, underscoring what the Company believes could be a major new commercial opportunity in the large and underserved global insomnia market.

Newly Released Vida^® Data Supports Potential

Form 8-K Vivos Therapeutics, Inc. For: Jun 25

Thu, 25 Jun 2026 17:22:00 -0400
si-local-file:///var/storage/secattach/20260625/26693543.html

Form 8-K Vivos Therapeutics, Inc. For: Jun 25

Thu, 25 Jun 2026 17:22:00 -0400
si-local-file:///var/storage/secattach/20260625/26693543.html

Vivos Therapeutics extends Streeterville debt conversion deal to August

Mon, 22 Jun 2026 08:30:33 -0400

Vivos Therapeutics, Inc. (NASDAQ: VVOS) has extended its strategic financing agreement with Streeterville Capital, LLC through August 31, 2026, according to a press release from the Littleton, Colorado-based medical device company.

Under the extended terms, Streeterville reaffirmed its commitment to convert up to $4.5 million of outstanding debt into a combination of perpetual, non-convertible preferred stock and shares of Vivos common stock. The conversion is structured to begin once Vivos raises $2.6 million in equity and can continue up to the $4.5 million maximum.

The original agreement, announced earlier in June 2026, set a deadline of June 15. Vivos said that timeframe

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Mon, 22 Jun 2026 08:30:00 -0400

LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it has entered into an extension of its previously announced strategic financing agreement with Streeterville Capital, LLC (“Streeterville”).

Under the extended agreement, Streeterville has extended the timeframe of the arrangement through August 31, 2026 and reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Mon, 22 Jun 2026 08:30:00 -0400

LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it has entered into an extension of its previously announced strategic financing agreement with Streeterville Capital, LLC (“Streeterville”).

Under the extended agreement, Streeterville has extended the timeframe of the arrangement through August 31, 2026 and reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Mon, 22 Jun 2026 08:30:00 -0400

LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it has entered into an extension of its previously announced strategic financing agreement with Streeterville Capital, LLC (“Streeterville”).

Under the extended agreement, Streeterville has extended the timeframe of the arrangement through August 31, 2026 and reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Mon, 22 Jun 2026 08:30:00 -0400

LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it has entered into an extension of its previously announced strategic financing agreement with Streeterville Capital, LLC (“Streeterville”).

Under the extended agreement, Streeterville has extended the timeframe of the arrangement through August 31, 2026 and reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a

Form 8-K Vivos Therapeutics, Inc. For: Jun 16

Tue, 16 Jun 2026 17:03:00 -0400
si-local-file:///var/storage/secattach/20260616/26655116.html

Form 8-K Vivos Therapeutics, Inc. For: Jun 16

Tue, 16 Jun 2026 17:03:00 -0400
si-local-file:///var/storage/secattach/20260616/26655116.html

Form 8-K Vivos Therapeutics, Inc. For: Jun 15

Tue, 16 Jun 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260616/26649835.html

Form 8-K Vivos Therapeutics, Inc. For: Jun 15

Tue, 16 Jun 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260616/26649835.html